Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

109.64 -4.90 (-4.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
61 62 Next >
Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
From Gilead Sciences, Inc.
Via Business Wire
Lattice Semiconductor To Rally 33%? Here Are 10 Other Analyst Forecasts For Tuesday
Goldman Sachs boosted the price target for Kaiser Aluminum Corporation (NASDAQ: KALU) from $70 to $80. Goldman Sachs analyst Emily Chieng maintained a Sell rating on the stock. Kaiser Aluminum shares... 
Via Benzinga
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends. 
Via Talk Markets
ARK Invest: The 7 Words That Explain Why Wall Street Can’t Stand Cathie Wood
Why does Wall Street hate Cathie Wood and her ARKK ETF? Seven words show how her focus on innovation divides investors. 
Via InvestorPlace
Gilead Issues Unexpectedly Bullish Outlook After Cancer Drug Sales Rocket
The company posted another massive quarter for cancer treatment sales. 
Via Investor's Business Daily
Mount Gilead, OH Author Publishes Children's Book
This Kids Book Features the Cutest Baby Elephant You Will Ever See! 
Via PR Leap
Europe Liver Cancer Therapeutics Market to Reach at High CAGR of 8.95% by 2023-2030
The Europe liver cancer therapeutics size was valued at US$ 384 million in 2022 and is estimated to reach US$ 627 million by 2030, growing at a CAGR of 8.95% during the forecast period (2023-2030) 
Via SBWire
Kite's Tecartus CAR T-Cell Therapy Demonstrates Durable Overall Survival Benefit In Leukemia Settings
Kite, a Gilead Sciences Inc (NASDAQ: GILD) company, announced the three-year follow-up results from the pivotal ZUMA-3 study of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel).  
Via Benzinga
2 Biotech Stocks That Could Make You Richer
Patience will pay off with these two stocks. 
Via The Motley Fool
Kite’s Tecartus® CAR T-Cell Therapy Demonstrates Overall Survival Benefit in Three-Year Follow-up of Pivotal ZUMA-3 Trial in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
From Gilead Sciences, Inc.
Via Business Wire
Earnings Outlook For Gilead Sciences
Via Benzinga
Thoughts For Thursday: Risk-off, Risk-on
The one foot forward, one foot backward action continues on Wall Street, though yesterday it was more like three or four steps backward. It seems Q1 earnings jitters are responsible. 
Via Talk Markets
NeurAxis: Should You Buy This IPO?
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype. 
Via Talk Markets
Europe Liver Cancer Therapeutics Market Is at the Cusp of Crossing CAGR of 8.95% N 2023-2030
Global Europe Liver Cancer Therapeutics Market to Witness Huge Growth by Key Players: Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, Eli Lilly, Bristol-Myers Squibb Company, Gilead... 
Via SBWire
Topics Death
Is Biotech Immunocore About To Make A 25% Price Move?
Small-cap Immunocore has been a price leader within the biotech industry. Analysts have a "buy" rating on the stock and estimate that it will move 25% higher. 
Via MarketBeat
Topics ETFs
NeurAxis IPO Sets Stage To Take On Irritable Bowel Syndrome With A Non-Surgical Solution
As NeurAxis gears up for its upcoming IPO, we take a deep dive into the company to see if it's worth adding to your investment portfolio. 
Via Talk Markets
Is Gilead Sciences a Good Stock to Buy Now?
Gilead Sciences' breast cancer drug, Trodelvy, just took a big step forward. 
Via The Motley Fool
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
The major indexes continued to run despite mixed-to-weak earnings. 
Via Investor's Business Daily
Gilead Sciences' Trovelvy Scores FDA Approval For Advanced/Metastatic Breast Cancer Setting
Via Benzinga
'Risk Of Overheating': 4 Experts On Hot January Jobs Report, How The Fed Will React
The SPDR S&P 500 ETF Trust (NYSE: SPY) traded lower Friday after the Labor Department reported blowout U.S. jobs market numbers from January. 
Via Benzinga
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact
Trading in the U.S. index futures suggests stocks may end a solidly positive week on a negative note. That said, the data-dependency of the Fed places the onus of providing trading cues to each... 
Via Benzinga
Is Gilead Sciences Stock a Screaming Buy After Its Strongest Results in 7 Years?
Gilead's strongest growth since 2015 comes with an asterisk. 
Via The Motley Fool
Gilead Sciences (GILD) Q4 2022 Earnings Call Transcript
GILD earnings call for the period ending December 31, 2022. 
Via The Motley Fool
Why Gilead Sciences Stock Is Trading Higher After Hours
Gilead Sciences Inc (NASDAQ: GILD) shares are trading higher in Thursday's after-hours session after the company reported  
Via Benzinga
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Liposome Drug Delivery Market 2023 in-Depth Analysis, Growth, Size, Future Prospect, Regional Development and Global Outlook 2029
Liposome Drug Delivery Market Size, Share and Forecast 2023-2029 Key Players are – Ipsen Pharma, Celsion Corp, Gilead Sciences, Astellas Pharma, Johnson & Johnson, Luye Pharma Group, Novartis AG 
Via SBWire
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
The index futures point to a mixed opening on Thursday, as tech earnings continue to be encouraging. 
Via Benzinga
Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.